WO2024141955 - RNA COMPOSITIONS TARGETING HIV
National phase entry is expected:
Publication Number
WO/2024/141955
Publication Date
04.07.2024
International Application No.
PCT/IB2023/063293
International Filing Date
27.12.2023
Title **
[English]
RNA COMPOSITIONS TARGETING HIV
[French]
COMPOSITIONS D'ARN CIBLANT LE VIH
Applicants **
BIONTECH SE
Inventors
LE DOUCE, Valentin
TOLKSDORF, Felix
NELKE, Johannes
BOROS, Gábor
REINHOLZ, Jonas
KARIKÓ, Dr. Katalin
BESSONOV, Sergey
Priority Data
63/477,460
28.12.2022
US
63/517,542
03.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 14669 | |
| EPO | Filing, Examination, Granting | 80713 | |
| Japan | Filing, Examination, Granting | 3945 | |
| South Korea | Filing, Examination, Granting | 5751 | |
| USA | Filing, Examination, Granting | 20740 |
Total:
125,818
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.[French]
La présente invention concerne des compositions (par exemple, des compositions pharmaceutiques) pour l'administration d'agents d'anticorps anti-VIH et des technologies associées (par exemple, des constituants de ceux-ci et/ou des procédés associés). Entre autres, la présente invention concerne des polyribonucléotides codant pour une chaîne d'immunoglobuline d'un agent d'anticorps anti-VIH.